Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Assessment of Substrate for Ventricular Tachycardia With Hemodynamic Compromise

John Whitaker*, Radhouene Neji†,2, Steven Kim†, Adam Connolly†, Thierry Aubriot†, Justo Juliá Calvo†, Rashed Karim†, Caroline H. Roney†, Brendan Murfin†, Carla Richardson†, Stephen Morgan†, Tevfik F. Ismail†,1, James Harrison†, Judith de Vos†, Maurice C. G. Aalders†, Steven E. Williams†,7, Rahul Mukherjee†, Louisa O’Neill†, Henry Chubb†, Cory Tschabrunn†, Elad Anter†, Luigi Camorota†, Steven Niederer†, Sébastien Roujol†, Martin J. Bishop†, Matthew Wright†, John Silberbauer†, Reza Razavi† and Mark O’Neill†

*Correspondence: John Whitaker john.whitaker@kcl.ac.uk
†ORCID: Steven E. Williams orcid.org/0000-0002-7266-2084

Background: The majority of data regarding tissue substrate for post myocardial infarction (MI) VT has been collected during hemodynamically tolerated VT, which may be distinct from the substrate responsible for VT with hemodynamic compromise (VT-HC). This study aimed to characterize tissue at diastolic locations of VT-HC in a porcine model.

Methods: Late Gadolinium Enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging was performed in eight pigs with healed antero-septal infarcts. Seven pigs underwent electrophysiology study with venous arterial-extra corporeal membrane oxygenation (VA-ECMO) support. Tissue thickness, scar and heterogeneous tissue (HT) transmurality were calculated at the location of the diastolic electrograms of VT-HC.

Results: Diastolic locations had median scar transmurality of 33.1% and a median HT transmurality 7.6%. Diastolic activation was found within areas of non-transmural scar in 80.1% of cases. Tissue activated during the diastolic component of VT circuits was thinner than healthy tissue (median thickness: 5.5 mm vs. 8.2 mm healthy tissue, \( p < 0.0001 \)) and closer to HT (median distance diastolic tissue: 2.8 mm vs. 11.4 mm healthy tissue, \( p < 0.0001 \)). Non-scarred regions with diastolic activation were closer to steep gradients in thickness than non-scarred locations with normal EGMs (diastolic locations distance = 1.19 mm vs. 9.67 mm for non-diastolic locations, \( p < 0.0001 \)). Sites activated late in diastole were closest to steep gradients in tissue thickness.
INTRODUCTION

Viable myocytes within and on the border of dense scar display abnormal electrophysiological characteristics that promote reentrant arrhythmias (1–3). In most clinical VT ablation procedures, electrophysiological criteria alone are normally used to identify arrhythmogenic tissue (4–6). Even with a combination of ablation of clinical VT identified through activation and entrainment mapping and pace-mapping as well as substrate-based ablation (7), medium term outcomes remain modest with up to 50% of patients experiencing a recurrence of VT within a year of ablation (8).

When imaged ex-vivo at the near-cellular level, late-gadolinium enhanced (LGE) cardiovascular magnetic resonance (CMR) accurately identifies peri-infarct heterogeneous tissue (HT) as regions of intermediate signal intensity (ISI) (9). This tissue represents the critical substrate responsible for post-MI reentrant VT (10). These observations have been extended to in-vivo imaging where it has been reported that regions of ISI may also display abnormal electrophysiological properties (11, 12) described as the peri-infarct borderzone (BZ). This suggests that in-vivo LGE-CMR may offer a low-risk option for generating a 3D assessment of substrate that may have utility in guiding substrate-based VT ablation.

Pre-procedural cross-sectional imaging has been proposed as a non-invasive approach that may facilitate more comprehensive arrhythmogenic substrate identification and ablation (13). Effective substrate identification, either using electrophysiological or structural criteria, may be of particular importance in the context of the growing population of patients presenting with VT with hemodynamic compromise (VT-HC) (14, 15), in which only a substrate-guided approach is usually possible (6).

We hypothesized that under idealized experimental conditions the quality of LGE-CMR could be optimized in order provide accurate anatomic information about the tissue substrate for VT-HC. We aimed to characterize the tissue substrate responsible for VT-HC using high-resolution in-vivo 3D LGE-CMR and acquiring high-density activation mapping under hemodynamic support to identify the location of diastolic electrograms during post-MI VT-HC in a chronic porcine infarct model.

MATERIALS AND METHODS

Animal studies complied with French law and were performed at the Institut de Chirurgie Guidée par l’image (IHU), Strasbourg, France. The experimental protocol was approved by the local and national institutional animal care and ethics committee. Eight domestic pigs underwent a 180 minute balloon occlusion of the mid left anterior descending (LAD) artery to create experimental ischemia-reperfusion myocardial infarction (MI) as previously described (16). Seven weeks following MI each pig underwent late-gadolinium enhanced (LGE) cardiovascular magnetic resonance (CMR) imaging. One week later each pig underwent electrophysiology study with prophylactic hemodynamic support during which VT was induced and assessed using high-density activation mapping.

Conclusions: Non-transmural scar, mildly decreased tissue thickness, and steep gradients in tissue thickness represent the structural characteristics of the diastolic component of reentrant circuits in VT-HC in this porcine model and could form the basis for imaging criteria to define ablation targets in future trials.

Keywords: ventricular tachycardia, late gadolinium enhancement, cardiovascular magnetic resonance, mechanical circulatory support, venous-arterial extra corporeal membrane oxygenation (VA-ECMO)
window = 7 mm; parallel imaging using GRAPPA with acceleration factor 2; resolution 1.2 x 1.2 x 1.2 mm³; FOV: 400 x 257 x 96 mm³; 2 R-R interval ECG triggering) with full ventricular coverage. Subjective and objective parameters of image quality were compared between 2D and 3D LGE CMR imaging (further details in Supplementary Figure 1).

CARDIOVASCULAR MAGNETIC RESONANCE IMAGING DATA ANALYSIS

Image Segmentation
Each 3D LGE-CMR scan was manually segmented by a single observer within Seg3D2 [University of Utah, Utah, USA, https://www.sci.utah.edu/cibc-software/seg3d.html]. Based on previously reported analysis of LGE-CMR imaging from patients undergoing VT ablation (17), the segmented myocardium was thresholded for scar signal intensity (SI_scar) at 60% and intermediate SI (SI_intermediate) at 40% of the highest SI within the segmentation.

Tissue Thickness and Scar Transmurality Assessment
Field lines between the endocardial and epicardial surfaces were derived by solving the Laplace equation as previously described (18). Briefly, the endocardial and epicardial surfaces were tagged. To calculate the distance from endocardial to epicardial surface, the Laplace equation ($\nabla^2 u = 0$) was solved with Dirichlet boundary conditions assigned at the endocardial ($u = 0$) and epicardial ($u = 1$) surfaces. Wall thickness was evaluated as the total length of the continuous path from the endocardium to the epicardium when moving orthogonally between adjacent iso-potential surfaces. Tissue thickness gradients were assessed using a radial basis function to identify the gradient in tissue thickness (further details in Supplementary Materials). Transmurality of scar and HT was defined as the proportion of nodes along the path between endocardium and epicardium corresponding to each tissue type. The distance of each endocardial node to the nearest neighboring node assigned as heterogeneous tissue (HT) was automatically calculated.

Segments were processed to generate a surface mesh containing endocardial and epicardial surfaces, scar and aorta in the Digital Image Fusion (DIF) format for import into the Precision Electroanatomic Mapping System (EAMS, Abbott, St Paul, MN, USA) within which they were registered with the EAMS geometry, as described below.

Electrophysiology Study and Hemodynamic Support
Electrophysiology procedures were conducted 8 weeks after MI under general anesthetic (further details in Supplementary Materials) using the Precision electro-anatomic mapping system (EAMS, Abbott, Chicago, IL).

Prior to the EP study pigs were established on venous-arterial extra-corporal membrane oxygenation (VA-ECMO) via the left femoral artery and vein and hemodynamic support was prophylactically instituted using a Maquet Cardiohelp machine (Maquet Getinge group, Rastatt, Germany, see Supplementary Figure 1). Venous and arterial access was established for the EP study and hemodynamic monitoring/drug administration. Hemodynamic compromise (HC) was defined as a rhythm associated with a mean arterial pressure (MAP) below 50 mmHg or a pulse pressure lower than 20 mmHg. During rhythms not associated with HC, VA-ECMO circuit flow was reduced to 0.5 L/min. During rhythms associated with HC, VA-ECMO flow ranged between 0.5 and 1 L to 4 L depending on hemodynamic status to maintain a MAP of 65–70 mmHg. Further details are provided in the Supplementary Materials.

A sensor-enabled Abbott FlexAbility™ ablation catheter was advanced to the aorta via the right femoral artery and used to acquire aortic root and coronary ostia geometry prior to gaining retrograde left ventricular (LV) access across the aortic valve. A multipolar mapping catheter [HD Grid™ or LiveWire™ duo-deca (Abbott, Chicago, IL)] was advanced through an Agilis sheath via the aorta to acquire LV endocardial geometry.

LV endocardial activation maps were acquired while pacing from the RV apex at 500 ms and then 300 ms.

An attempt was made to induce ventricular tachycardia (VT) using an adapted Wellen’s VT stimulation protocol (19) with up to four extra-stimuli from right and then left ventricular sites. In the event that no VT was induced, the non-selective beta agonist isoproterenol was commenced as an infusion at an initial rate of 2 µg/min and up titrated to a maximum rate of infusion of 20 µg/min during which programmed electrical stimulation was repeated.

Activation maps were acquired using the Automap function within Precision™ using the initial deflection seen on any lead of the surface ECG as the timing reference with strict settings applied (EAMS, Abbott, St Paul, MN, USA) (Score = 85; speed limit = 10 mm/s; distance 1 mm; enhanced noise rejection: off). Each individual bipolar and unipolar EGM from the mapped VTs and maps during pacing were subsequently reviewed offline and the activation time reassigned when necessary. Following spontaneous or pace-termination, VT induction and mapping was subsequently repeated. Final activation maps were reviewed by at least two experienced electrophysiologists.

The extent of conduction block (identified as regions with tightly spaced isochrones in which > 15 ms separated adjacent activation points; in which activation on either side of tightly spaced isochrones from wave fronts moving in different directions, and in which double potentials identified in proximity to the boundary between adjacent waves of conduction) during RV pacing and during each mapped VT was estimated using the surface distance function within the EAMS.

Co-registration of Imaging and Electrophysiological Data
After the EP study, using the re-map function within the EAMS, a surface mesh generated from the LGE-CMR scan was imported into the EAMS in the digital image fusion (DIF) format. The EAMS LV geometry was registered to the DIF.
model with an initial landmark-based registration with the aorta, coronary ostia and LV apex as initial fiducial landmarks, followed by surface registration using the proprietary surface registration function within the EAMS. EAMS points manually identified as having healthy EGMs during RVP and those demonstrating diastolic activation during VT were exported from the EAMS. The location of these points from the EAMS mesh were automatically mapped to nodes on the CMR derived mesh within a 1 mm radius, to allow a node-wise assessment of the structural characteristics of tissue demonstrating diastolic activation during VT and healthy tissue could be made.

Episcopic Auto-Fluorescence Cryomicrotome Imaging
Following euthanasia, each heart was processed and then imaged using episcopic auto-fluorescence cryomicrotome imaging as previously described (20) (see Supplementary Figure 2).

Statistical Analysis
Normality of distribution of variables was assessed using the Shapiro-Wilks test. Normally distributed continuous variables are expressed as mean ± SD, otherwise variables are reported as medians with interquartile ranges. Normally distributed data were compared using a two tailed, paired sample t-test.
Ordinal and non-parametric continuous data were compared using a Mann-Whitney U test or Kruskal-Wallis H-test as appropriate, with pairwise comparisons performed using Dunn’s (1964) procedure with a Bonferroni correction for multiple comparisons where appropriate in which case adjusted p-values are presented. Two-tailed values of p < 0.05 were considered significant. Statistical analysis was carried out in SPSS (v24, IBM Corporation, New York).

RESULTS

One post-MI pig died after CMR imaging and prior to EP study. The study protocol was completed in the remaining seven post-MI pigs and two control pigs who did not undergo CMR imaging. During this study all the VT that was induced was associated with hemodynamic compromise as defined above.

Late Gadolinium Enhanced Imaging Under Contrast Steady State

3D LGE-CMR imaging was acquired in eight animals (weight 62.6+/−3.7 kg) in the supine position under general anesthesia and CSS achieved in seven animals. In a single animal failure of the peripheral cannula interrupted the continuous Gd infusion, which prevented CSS during imaging. In the remaining seven animals 3D LGE-CMR imaging was acquired using a total Gd dose of <0.2 mmol/kg. 3D LGE-CMR was acquired in mid-diastole with a data acquisition duration of 83–104 ms, 23–42 segments, and a total imaging time of 50+/−12 min. Under conditions of CSS mean variation in T1\text{myocardium} was 5.2% (±3.1%, range 2.6–9.3%) and mean variation in T1\text{blood} was 9.8% (±2.1%, range 6.7–13.5%). Representative imaging examples and demonstration of CSS are shown in Figure 1. All 3D LGE-CMR imaging is available for review online (Supplementary Material).

A comparison of the image quality with clinical standard 2D LGE-CMR imaging was undertaken and is included in the Supplementary Materials.

Induced Ventricular Tachycardia

Twenty episodes of VT-HC demonstrating a macro reentrant pattern of activation were mapped (18 complete maps, 2 incomplete) and the locations of diastolic electrograms (EGMs) assessed to be part of the reentrant circuit were identified and labeled. A summary of the characteristics of the induced VTs is shown in Table 1. All mapped VTs were dependent on at least one region of conduction block that was not evident during RVP500. All VTs with a complete activation map demonstrated at least two distinct regions of conduction block.

There was an increase in the extent of conduction block between RVP500 and VT (mean increase = 45 mm, 95% CI 27–63 mm, p < 0.001) and between RVP360 and VT (mean increase 23 mm, 95% CI 5–42 mm, p = 0.016), and a trend toward, an increase in conduction block between RVP500 and RVP360 (mean increase = 22 mm, 95% CI 1–45 mm, p = 0.059). Pearson correlation coefficient demonstrated a negative correlation between activation rate and total extent of conduction block (r² = 0.288, p = 0.001). These data are illustrated in Figure 1. Entrainment mapping was attempted in a subset of the induced VT-HC but was not successful due to failure to entrain or degeneration of the VT to ventricular fibrillation (VF).

Tissue Structure Assessment With in-vivo CMR at Locations With Diastolic Activation

Representative examples of diastolic EGMs recorded during VT are shown with their corresponding locations on in-vivo CMR in Figure 2. As shown in these examples, diastolic EGMs were visualized in regions with subendocardial HT (location 1), near-transmural scar (location 2) and pure HT (location 3). Tissue thinning is also seen in all locations.

A representative example of the position of a diastolic EGM, corresponding in-vivo imaging and episcopic auto-fluorescence cryomicrotome imaging (EACI) data is shown in Figure 3.

Non-enhanced tissue adjacent to regions of enhancement on in-vivo CMR were frequently observed in the septal area and corresponded to regions where muscle fibers traversing the RV cavity, including the moderator band, inserted into the septum. An example of this is shown in Figure 4, in which a corridor of preserved myocardium surrounded by dense scar forms the principal path of the diastolic isthmus of one VT, which in this case is approximately aligned with the direction of the long axis of the left ventricle.

The structural characteristics of locations at which diastolic EGMs occurred during the observed VTs were systematically examined and compared with locations at which normal EGMs were recorded. The normal EGMs were all recorded at positions with 0% scar/HT transmurality. Diastolic locations had a median scar transmurality of 33.1%, [IQR 0–77.3%, mean 37.4(±36.3)%, p < 0.001] and a median HT transmurality 7.6% [IQR 0–30.3%, mean 18.3(±22.9)% p < 0.001]. The majority (80.1%) of diastolic locations were found within areas with non-transmural scar or HT. Tissue activated in the diastolic component of VT circuits was thinner than healthy tissue (median thickness tissue with diastolic activation = 5.5 mm vs. 8.2 mm healthy tissue, p < 0.001) and was closer to HT (median distance from HT diastolically activated tissue 2.8 mm vs. 11.4 mm healthy tissue, p < 0.001). Of those diastolic locations that were in regions without scar or HT, all were within 15 mm of HT and

| Pig | Number of episodes of non-sustained VT | Number of sustained, unmapped VTs | Number of mapped VTs | Number of episodes of VF |
|-----|--------------------------------------|----------------------------------|----------------------|-------------------------|
| 1   | 67                                   | 3                                | 0                    | 7                       |
| 2   | -                                    | -                                | -                    | -                       |
| 3   | 27                                   | 2                                | 4                    | 1                       |
| 4   | 100                                  | 3                                | 9                    | 4                       |
| 5   | 22                                   | 2                                | 2                    | 6                       |
| 6   | 16                                   | 3                                | 2                    | 10                      |
| 7   | 88                                   | 2                                | 2                    | 1                       |
| 8   | 47                                   | 3                                | 2                    | 8                       |
89% lay within 10 mm of HT. These results are illustrated in Figure 5.

**Non-scarred Regions With Diastolic Activation During Ventricular Tachycardia**

Approximately 20% of diastolic points had 0% scar/HT on in-vivo CMR. As noted, all regions activated during diastole during VT-HC were within 15 mm of HT. An example of EGMs recorded from a reentrant VT-HC is shown in Figure 6. In this example, early diastolic activation is identified within non-scarred tissue, before the wavefront continues into a region demonstrating non-transmural scar in which the remainder of the isthmus is located. On the corresponding in-vivo CMR and EACI data the EGMs are located adjacent to a sharp gradient in tissue thickness just outside the thinned scar region. When all locations without scar were considered, locations with diastolic activation were closer to steep gradients in tissue thickness than non-diastolic locations (diastolic locations distance = 1.2 mm (IQR 0–3.6 mm) vs. 9.7 mm (IQR 2.9–18.6 mm) for non-diastolic locations, p < 0.001). When diastolic locations were classified according to whether they demonstrated early, mid or late activation within the diastolic window, defined as being from the end of the QRS complex on the surface ECG, the median distance to regions of steep gradient in tissue thickness was lowest at late-diastolic sites (distance = 1.5 mm), followed by early-diastolic sites (distance = 2.8 mm) and greatest at mid-diastolic sites (distance = 3.9 mm, p < 0.001 for group differences and p < 0.001 for all pairwise comparisons).

**DISCUSSION**

In a chronic porcine infarct model high resolution 3D LGE-CMR acquired during contrast steady state can be used to define the structural characteristics of components of post-infarct reentrant VT circuits. Our data demonstrate that the majority of diastolic locations in this model of VT-HC are located in regions with non-transmural (<95%) scar/HT with lower tissue thickness than healthy tissue. In addition, ∼20% of diastolic points during VT-HC are in non-scarred tissue that is adjacent to steep gradients in tissue thickness.

**Late-Gadolinium Enhanced Imaging Under Conditions of Contrast Steady State**

Establishing CSS was technically feasible and resulted in stable TI_{myocardium} for prolonged periods during image acquisition. For high-resolution 3D imaging sequences used in previous...
Supplementary Figure 3). While in this study we did not feel low contrast between blood pool and scar prohibited confident identification of the blood-myocardial interface, the differentiation of endocardial scar from the blood pool could be improved in subsequent studies through using a lower flip angle. We note that this issue is encountered to some degree in all bright-blood LGE sequences and represents a motivation to the development of dark blood sequences to overcome this effect (27).

Transmurality of Scar

The calculated transmurality of scar in locations with diastolic activation reported here is lower than has been reported previously. In previous reports, mean scar transmurality at VT isthmus sites assessed using 2D 1.4 x 1.4 x 8 mm3 LGE-CMR with scar segmented according to a Full-width at half-maximum (FWHM) threshold was 60 ± 38% (28) or using a similar 2D LGE-CMR imaging 66 ± 22%, which rose to 76 ± 16% at sites of concealed entrainment and to 70 ± 21% at termination sites (29). The use of 2D imaging, bolus contrast administration and different image analysis protocols used in previous experiments is likely to contribute to observed differences in scar transmurality. In addition, there may be mechanistic differences between the VT-HC described here and VTs studied previously, both of which included at least some hemodynamically tolerated VTs. Early reports of hemodynamically tolerated scar-mediated VT often localized the isthmus to within a thin walled LV aneurysm, which would likely be identified on CMR imaging as transmural scar (30, 31). In contrast, the re-entrant VT-HC observed in this study displayed a greater dependence on
functional rather than fixed conduction block, suggesting that the structural substrate of VT-HC may be distinct from slower and hemodynamically tolerated VTs. In addition, the use of high-resolution imaging and the measures taken to minimize artifact in this report may have contributed to an increased sensitivity for the identification of tissue with preserved viability and reduced the calculated scar transmurality at sites with diastolic activation.

**Tissue Thickness**
Tissue thickness has been demonstrated to be a sensitive structural marker for arrhythmogenic tissue in the post-MI
FIGURE 5 | Tissue characteristics of diastolic locations. (A) Example of LGE CMR derived endocardial shell color coded according to scar transmurality and demonstrating antero-septal infarction. Histogram shows combined scar/heterogeneous tissue (HT) transmurality pooled from all locations activated during diastole in all pigs. (B) Example of LGE CMR derived endocardial shell color coded according to tissue thickness. Histogram shows tissue thickness pooled from all diastolic locations (blue) in all pigs compared with tissue thickness at the location of normal EGMs pooled from all pigs (red). (C) Example of LGE CMR derived endocardial shell color coded according to distance from HT. Histogram shows distance from HT pooled from all diastolic locations in six pigs.
FIGURE 6 | Non-scarred tissue demonstrating diastolic activation during VT. (A) Activation map during VT demonstrating diastolic activation during VT (yellow to purple) with a converging pattern of activation toward a narrow channel (green) which subsequently widens prior to multiple systolic breakouts (red). (B) In-vivo CMR derived shell with translucent mesh of scar overlaid and color coded according to HT transmурality. The location of 3 early diastolic EGMs is indicated by red spheres. (C) Early diastolic EGM, short axis (SAX) in-vivo CMR and corresponding EACI imaging at locations 1, 2 and 3 demonstrating location of EGMs in tissue proximal to scar, but without enhancement in the wall at this location.
LV when assessed using coronary computed tomographic angiography (CCTA) (32). Among patients undergoing catheter ablation of drug refractory post-MI scar-related VT, 98% have been reported to demonstrate wall thinning on CCTA (32). As well as demonstrating a strong relationship between low voltage regions and local abnormal ventricular activations (LAVA), 89% of RF termination sites were located within the imaging substrate [defined as regions of wall thinning (tissue thickness < 5 mm) or severe wall thinning (tissue thickness < 2 mm)], with the majority of these located within 10 mm of the margin. The data presented here also indicate that regions of diastolic activation during VT-HC tend to be thinner than healthy tissue. However, examination of the histograms shown in Figure demonstrates that there is significant overlap between the tissue thickness assessed with diastolic activation and healthy tissue, and therefore tissue thickness alone would not adequately differentiate regions of diastolic activation during VT from healthy tissue. In the present study, the shorter VT cycle length and dependence of the VTs on functional rather than fixed anatomical conduction block, as might be expected in an aneurysm demonstrating severe wall thinning, suggests a possible explanation for why diastolic activation during VT was observed in tissue with a wider range of thicknesses than in previous reports which have used CT imaging.

**Non-enhancing Tissue Activated During Diastole in VT**

Approximately 20% of diastolic locations present were found in locations with no scar/HT identified on in-vivo imaging. This tissue was located in close proximity to HT and adjacent to steep gradients in tissue thickness. The diastolic activation of such tissue has not been previously demonstrated in the reentrant paths of hemodynamically tolerated VT. This tissue may include regions of tissue with microscopic fibrosis that occurs adjacent to scar and that is not identified by in-vivo LGE-CMR imaging but is likely to demonstrate distinct electrophysiological properties that promote its participation in VT-HC. Intrinsic tissue anisotropy at the scar interface, which may be enhanced in diseased ventricular tissue (33), is also likely to affect conduction behavior in this region. In canine models of scar related re-entry, it is established that the arc of functional conduction block responsible for the initiation of reentry localizes to regions of sharp gradients in tissue thickness and previous experiments have demonstrated that conduction velocity during pacing in this model is slower in regions of steep gradients in tissue thickness (34). In addition, the lowest conduction velocity (CV) in the re-entrant circuits of VTs in the same model may be found at exit sites (35). A wave of depolarization slows when transitioning from a small to a larger body of tissue due to the dispersion of the small source transmembrane current to a large number of downstream cells (source-sink mismatch) (36) and due to wavefront curvature that is a consequence of the geometric expansion of tissue encountered by a propagating wavefront. These observations suggest a mechanistic explanation for the diastolic activation of non-scarred tissue adjacent to steep gradients in tissue thickness in the reentrant path of VT-HC defined by functional conduction block, and the greatest proximity of the late diastolic component to these areas.

**Unique Anatomical Characteristics of the Isthmus**

In this study, tissue with scar/HT transmurality and tissue thickness across a wide range has been identified as activated during the diastolic component of the reentrant VT-HC studied. In a previous study of porcine post-MI VT-HC (10), despite high-resolution ex-vivo CMR (0.4 x 0.4 x 0.4 mm³), anatomical features distinguishing HT harboring diastolic activation during VT from non-participating HT were not identified. At a histological level, structural differences exist between regions harboring a critical diastolic isthmus that distinguish this tissue from other HT (37). However, since it was impossible to identify these differences using high resolution ex-vivo CMR, it is extremely unlikely that such arrhythmogenic HT would be distinguishable from non-arrhythmogenic HT with CMR at current in-vivo resolution. The tissue in which the diastolic isthmus of VT-HC is expected to be located has been characterized in this model, however the current data does not indicate that within regions of non-transmural scar/HT, arrhythmogenic and non-arrhythmogenic substrate may be differentiated.

**Limitations**

Activation mapping alone was used to characterize the VT-HC circuits in this study. Entrainment mapping to confirm participation of the regions with diastolic activation was attempted but not routinely achieved and this represents a limitation of the presented data. The registration of electrophysiology and imaging data represents a major challenge when attempting to establish the structural basis for observed electrophysiological phenomena. Despite meticulous care in the registration between LGE-CMR and EAMS data, it is acknowledged that registration error has not been avoided entirely. Establishing the correct rotation around the long axis of the LV remains a significant challenge even with the use of coronary ostia and other anatomical landmarks as guidance. Change in the shape of the LV between the time of electrophysiology procedures and imaging are expected due to differences in the loading conditions, which represents an additional challenge, as do absolute limitations in the accuracy of the localization of EGM signals. The degree to which registration error affects the accuracy of results is difficult to quantify and is not accurately described by surface distance between EAMS and imaging data. There is no consensus regarding the optimal threshold to apply in order to accurately identify scar on LGE-CMR (25). The challenge of quantitatively assessing scar and fibrosis are compounded by differences in imaging parameters and contrast administration protocols, which will affect degree of hyperenhancement of tissue. The absence of standard histological data from this study due to the destructive nature of the EACI process is a further limitation of the current study and prohibits formal validation of the imaging data. Common to most large animal pre-clinical studies, this study included a relatively small number of animals, in consideration of minimizing the use of animals in experiments and cost. Despite
these limitations, the comparison between LGE-CMR and high density electrophysiological mapping data demonstrate that the imaging acquired and processing strategy reliably identified electrophysiologically relevant tissue in this model.

CONCLUSIONS

The structural characteristics of the tissue demonstrating diastolic activation during reentrant VT-HC, including non-transmural scar, mildly decreased tissue thickness and steep gradients in tissue thickness, are likely to promote functional conduction block which is demonstrated to be an important mechanism underlying the VT-HC observed in this model. The late diastolic segment of activation during VT-HC is closest to steep gradients in tissue thickness which may be a contributory factor to the maximal wavefront slowing seen in this region. The characterization of the myocardial substrate for post-MI scar mediated VT-HC could form the basis for imaging criteria to define ablation targets during future trials.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by Animal studies complied with French law and were performed at the Institut de Chirurgie Guidée par l’image (IHU), Strasbourg, France. The experimental protocol was approved by the Local and National Institutional Animal Care and Ethics Committee.

AUTHOR CONTRIBUTIONS

JW: conceived and designed study, analyzed data and prepared first draft and subsequent modifications of the manuscript. RN and SR: designed and implemented CMR protocols, assisted in acquisition of imaging and contributed to analysis of data. SK: contributed to experimental design, assisted with acquisition of electroanatomic mapping data, and contributed to analysis of data. AC: key contribution to analysis of electrophysiologic data. TA: planning and acquisition of electrophysiological data. JC, MW, and JS: electrophysiologist who acquired electroanatomic mapping data. RK: developed computational tools for registration of imaging and electrophysiologic data. BM, CRi, SM, and LC: development of VA-ECMO protocol for hemodynamic support, delivery of hemodynamic support during electrophysiology studies. TI and JH: CMR reader. JV and MA: development of cryomicrotome imaging protocol and processing of tissue to acquire cryomicrotome imaging and approved submitted version of manuscript. SW, LO’N, RM, HC, RR, and MO’N: involved in acquisition of CMR and electrophysiologic data. RM: repeat segmentation of 3d LGE CMR imaging for inter-observer reproducibility. HC, RR, and MO’N: funding holder for study. SW, LO’N, RM, HC, RR, MO’N, CT, EA, SN, and MB: planning and study design. RR and MO’N: supervisory oversight of project. CT, EA, SN, MB, HC, RR, MO’N, RM, SW, LO’N, TI, JH, BM, CRi, SM, LC, CRo, RK, JC, MW, JS, TA, AC, SK, RN and SR: substantial modifications to previous drafts of manuscript and approved submitted version of manuscript. TA, JC, MW, JS, BM, CRi, SM, LC, CRo, TI, JH, RK, SW, LO’N, RM, CT, EA, SN, MB, HC, RR, and MO’N: analysis and interpretation of data. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by a Medical Research Council UK Clinical Research Training Fellowship (grant code MR/N001877/1) which funded JW; the Health Innovation Challenge Fund (HICF-R10-698), a parallel funding partnership between the Department of Health and the Wellcome Trust, the Wellcome Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering at King’s College London (WT203148/Z/16/Z); EPSRC grant (EP/R010935/1); National Institute for Health Research (NIHR) Biomedical Research Centre award to Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust in partnership with King’s College London, and by the NIHR Healthcare Technology Co-operative for Cardiovascular Disease at Guy’s and St Thomas’ NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The CardioHelp machine and all ECMO consumables were donated by Maquet, Getinge Group without conditions on their use. The Precision and Claris system and all EP mapping consumables were donated by Abbott without conditions on their use. This research was funded in whole, or in part, by the Wellcome Trust [Grant Number WT203148/Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted manuscript version arising from this submission. This project was supported by the National Institute of General Medical Sciences of the National Institutes of Health [Grant Numbers P41 GM103545 and R24 GM136986]. SW was supported by British Heart Foundation [Grant Number FS/20/26/34952].

ACKNOWLEDGMENTS

We are grateful to the Abbott UK, France and US teams who generously loaned the Precision and Claris systems for these experiments, provided outstanding technical support and donated all the EP mapping catheters, cables and consumables, Sagar Haval, Lynn Calvert and the Maquet, Getinge Group who generously provided a CardioHelp machine, provided technical support and donated all the ECMO consumables as well as Sophie Pernot and the staff at the Institute de Chirurgie Guidée par
REFERENCES

1. Mehra R, Zeller RH, Gough WB, El-Sherif N. Reentrant ventricular arrhythmias in the late myocardial infarction period: 9 electrophysiologic-anatomic correlation of reentrant circuits. Circulation. (1983) 67:11-24. doi: 10.1161/01.CIR.67.1.11

2. El-Sherif N, Smith RA, Evans K. Canine ventricular arrhythmias in the late myocardial infarction period. 8 epicardial mapping of reentrant circuits. Circ Res. (1981) 49:255-65. doi: 10.1161/01.RES.49.1.255

3. Qin D, Zhang Z-H, Caref EB, Boutjdir M, Jain P, El-Sherif N. Cellular and ionic basis of arrhythmia in postinfarction remodeled ventricular myocardium. Circ Res. (1996) 79:461–73. doi: 10.1161/01.RES.79.3.461

4. Stevenson WG, Friedman PL, Saxon LA, Kocovic D, Geest RJ, et al. CMR-based identification of critical isthmus sites of ischemic postinfarction ventricular arrhythmias with entrainment mapping. J Am Coll Cardiol. (1997) 29:1180–9. doi: 10.1016/S0735-1097(97)00065-X

5. Tung R, Mathurin N, Michowitz Y, Yu R, Buch E, Bradfield J, et al. Functional pace-mapping responses for identification of targets for catheter ablation of scar-mediated ventricular tachycardia. Circ Arrhythm Electrophysiol. (2012) 5:264-72. doi: 10.1161/CIRCEP.111.967976

6. Jais P, Maury P, Khairy P, Sacher F, Nault I, Komatsu Y, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. (2012) 125:2184–96. doi: 10.1161/CIRCULATIONAHA.111.043216

7. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. (2018) 138:e272–391. doi: 10.1161/CIRCEP.113.000264

8. Dukkipati SR, Koruth JS, Choudry S, Miller MA, Whang W, Reddy VY. Catheter ablation of ventricular tachycardia in structural heart disease: indications, strategies, and outcomes—part II. J Am Coll Cardiol. (2017) 70:2924–41. doi: 10.1016/j.jacc.2017.10.030

9. Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, et al. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. Circ Cardiovasc Imaging. (2010) 3:743-52. doi: 10.1161/CIRCIMAGING.108.835793

10. Ashikaga H, Sasano T, Dong J, Zviman MM, Evers R, Hopenfeld B, et al. Ashikaga H, Sasano T, Dong J, Zviman MM, Evers R, Hopenfeld B, et al. 10. Ashikaga H, Sasano T, Dong J, Zviman MM, Evers R, Hopenfeld B, et al. CMR Assessment VT Substrate

SUPPLEMENTARY MATERIAL

The Supplemental Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.744779/full#supplementary-material
29. Piers SRD, Everaerts K, Van Der Geest RJ, Hazebroek MR, Siebelink HM, Pison LAFG, et al. Myocardial scar predicts monomorphic ventricular tachycardia but not polymorphic ventricular tachycardia or ventricular fibrillation in nonischemic dilated cardiomyopathy. *Hear Rhythm.* (2015) 12:2106–14. doi: 10.1016/j.hrthm.2015.05.026

30. Josephson ME, Horowitz LN, Farshidi A, Spear JF, Kastor JA, Moore EN. Recurrent sustained ventricular tachycardia. 2 endocardial mapping. *Circulation.* (1978) 57:431–40. doi: 10.1161/01.CIR.57.3.440

31. Okumura K, Olshansky B, Henthorn RW, Epstein AE, Plumb VJ, Waldo AL. Demonstration of the presence of slow conduction during sustained ventricular tachycardia in man: use of transient entrainment of the tachycardia. *Circulation.* (1987) 75:369–78. doi: 10.1161/01.CIR.75.2.369

32. Yamashita S, Sacher F, Mahida S, Berte B, Lim HS, Komatsu Y, et al. Image integration to guide catheter ablation in scar-related ventricular tachycardia. *J Cardiovasc Electrophysiol.* (2016) 27:699–708. doi: 10.1111/jce.12963

33. Glukhov AV, Fedorov VV, Kalish PW, Ravikumar VK, Lou Q, Janks D, et al. Conduction remodeling in human end-stage nonischemic left ventricular cardiomyopathy. *Circulation.* (2012) 125:1835–47. doi: 10.1161/CIRCULATIONAHA.111.047274

34. Jang J, Whitaker J, Leshem E, Neissu U, Nakamori S, et al. Local conduction velocity in the presence of late gadolinium enhancement and myocardial wall thinning: a cardiac magnetic resonance study in a swine model of healed left ventricular infarction. *Circ Arrhythm Electrophysiol.* (2019) 12:e007175. doi: 10.1161/CIRCEP.119.007175

35. Anter E, Tschabrunn CM, Buxton AE, Josephson ME. High-resolution mapping of postinfarction reentrant ventricular tachycardia: electrophysiologic characterization of the circuit. *Circulation.* (2016) 134:314–27. doi: 10.1161/CIRCULATIONAHA.116.021955

36. Fast VG, Klkber AG. Cardiac tissue geometry as a determinant of unidirectional conduction block: assessment of microscopic excitation spread by optical mapping in patterned cell cultures and in a computer model. *Cardiovasc Res.* (1995) 29:697–707.

37. Dhanjal TS, Lellouche N, von Ruhland CJ, Abehsira G, Edwards DH, Dubois-Randé JL, et al. Massive accumulation of myofibroblasts in the critical isthmus is associated with ventricular tachycardia inducibility in post-infarct swine heart. *JACC Clin Electrophysiol.* (2017) 3:703–14. doi: 10.1016/j.jacep.2016.11.010

**Conflict of Interest:** The CardioHelp machine and all ECMO consumables were donated by Maquet, Getinge Group without conditions on their use. The Precision and Claris system and all EP mapping consumables were donated by Abbott without conditions on their use. The authors declare a potential conflict of interest and state it below. RN was employed by the company Siemens Healthcare. SK and TA were employed by the company Abbott Medical.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Whitaker, Neji, Kim, Connolly, Aubriot, Calvo, Karim, Roney, Murfin, Richardson, Morgan, Ismail, Harrison, de Vos, Aalders, Williams, Mukherjee, O’Neill, Chubb, Tschabrunn, Anter, Camporota, Niederer, Roujol, Bishop, Wright, Silberbauer, Razavi and O’Neill. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.